News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
IGI Laboratories, Inc. Announces the Submission of Two More ANDAs
November 21, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
FDA
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
November 2, 2026
·
2 min read
·
Heather McKenzie
Drug Development
Can Saudi Arabia’s burgeoning biotech hub withstand geopolitical pressures?
November 2, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie
